8-K: Immunocore Reports Strong Q3 Sales, Advances Pipeline

Immunocore Holdings plc announced robust third-quarter 2025 financial results, with KIMMTRAK net revenues growing 29% year-over-year, alongside significant progress in its Phase 3 clinical trials for melanoma and other therapeutic areas.

Summary

• KIMMTRAK net revenues reached $103.7 million in Q3 2025, a 29% year-over-year increase.
• Year-to-date KIMMTRAK net revenues were $295.5 million, up 31% from the same period in 2024.
• US quarterly sales growth for KIMMTRAK was 18% year-over-year, with mean duration of treatment increasing to 14 months.
• Europe and international regions saw 58% year-over-year quarterly sales growth for KIMMTRAK.
• Net loss for Q3 2025 was ($0.2) million, compared to a net profit of $8.7 million in Q3 2024.
• Basic and diluted net loss per share was ($0.00) for Q3 2025, down from $0.17 net income per share in Q3 2024.
• Cash, cash equivalents, and marketable securities totaled $892.4 million as of September 30, 2025.
• R&D expenses increased to $70.6 million in Q3 2025 from $52.8 million in Q3 2024, driven by autoimmune programs and Phase 3 trials.
• SG&A expenses rose to $39.8 million in Q3 2025 from $35.5 million in Q3 2024, supporting pipeline and global commercial expansion.
• The Independent Data Monitoring Committee (IDMC) selected 160 mcg as the go-forward dose for brenetafusp in the Phase 3 PRISM-MEL-301 trial.
• Enrollment for the Phase 3 TEBE-AM trial is on track to complete in 1H 2026.

Sentiment

Score: 6

Explanation: While revenue growth for KIMMTRAK is strong and the clinical pipeline is advancing, the shift from net profit to a net loss in Q3 2025, driven by increased R&D and SG&A expenses, indicates a negative financial trend for the quarter. However, the robust cash position and significant pipeline progress balance this, suggesting a moderately positive long-term outlook despite short-term profitability concerns.

Positives

• KIMMTRAK net revenues grew significantly by 29% year-over-year to $103.7 million in Q3 2025, demonstrating strong commercial momentum.
• Robust global expansion for KIMMTRAK, with 18% US sales growth and 58% growth in Europe and international regions.
• Mean duration of KIMMTRAK treatment in the US increased to 14 months, indicating sustained patient benefit and product efficacy.
• Strong cash position with $892.4 million in cash, cash equivalents, and marketable securities as of September 30, 2025, providing financial stability for ongoing operations and development.
• Advancement of multiple Phase 3 trials (TEBE-AM, PRISM-MEL-301) and mid-stage programs across oncology, infectious diseases, and autoimmune diseases.
• The Independent Data Monitoring Committee's (IDMC) recommendation of 160 mcg as the go-forward dose for brenetafusp in the PRISM-MEL-301 trial provides clarity and progress for a key pipeline asset.
• Expansion plans for KIMMTRAK into 2L+ advanced cutaneous melanoma (potential to address up to 4,000 previously treated patients) and adjuvant uveal melanoma (potential up to 1,200 HLA-A*02:01 positive, high-risk patients in US/Europe).

Negatives

• Net loss for Q3 2025 was ($0.2) million, a decline from a net profit of $8.7 million in Q3 2024.
• Basic and diluted net loss per share was ($0.00) in Q3 2025, compared to net income per share of $0.17 in Q3 2024.
• Increased Research and Development (R&D) expenses ($70.6 million vs. $52.8 million in Q3 2024) and Selling, General & Administrative (SG&A) expenses ($39.8 million vs. $35.5 million in Q3 2024) contributed to the net loss.
• Expected payment of approximately $65 million in sales-related rebate accruals in the fourth quarter of 2025.

Risks

• The impact of worsening macroeconomic conditions on the company's business, financial position, strategy, and anticipated milestones, including its ability to conduct ongoing and planned clinical trials.
• The company's ability to obtain a clinical supply of current or future product candidates or commercial supply of KIMMTRAK or any future approved products.
• The company's ability to obtain and maintain regulatory approval of its product candidates, including KIMMTRAK.
• The company's ability and plans in continuing to establish and expand a commercial infrastructure and to successfully launch, market, and sell KIMMTRAK and any future approved products.
• The company's ability to successfully expand the approved indications for KIMMTRAK or obtain marketing approval for KIMMTRAK in additional geographies in the future.
• The delay of any current or planned clinical trials, whether due to patient enrollment delays or otherwise.
• The company's ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all.
• Competition with respect to market opportunities.
• Unexpected safety or efficacy data observed during preclinical studies or clinical trials.
• Actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials or future regulatory approval.
• The company's need for and ability to obtain additional funding, on favorable terms or at all, including as a result of worsening macroeconomic conditions, including changes in inflation and interest rates and unfavorable general market conditions, and the impacts thereon of the war in Ukraine, the conflict in the Middle East, and global geopolitical tension.
• The company's ability to obtain, maintain, and enforce intellectual property protection for KIMMTRAK or any of its product candidates it or its collaborators are developing.
• The success of the company's current and future collaborations, partnerships, or licensing arrangements.

Future Outlook

Immunocore expects continued commercial momentum for KIMMTRAK, sustained investment in innovation, and advancement of its three Phase 3 melanoma trials and multiple mid-stage programs. The company anticipates completing enrollment for the Phase 3 TEBE-AM trial in the first half of 2026 and plans to file CTA/IND applications for its autoimmune candidates, IMC-S118AI in H2 2025 and IMC-U120AI in 2026. Approximately $65 million in sales-related rebate accruals are expected to be paid in Q4 2025.

Management Comments

• "Our commercial momentum continues with over $100 million in sales this quarter and enables sustained investment in innovation."
• "We are executing to plan – advancing three Phase 3 melanoma trials and multiple midstage programs – to deliver transformative outcomes for patients and sustained value for shareholders."

Industry Context

Immunocore operates in the highly competitive and innovative biotechnology sector, focusing on immunomodulating medicines. Its lead product, KIMMTRAK, is positioned as a standard of care in uveal melanoma, an area with significant unmet need. The company's expansion into 2L+ advanced cutaneous melanoma and adjuvant uveal melanoma, as well as its PRAME portfolio, addresses patient populations where improved progression-free survival and overall survival are still needed despite existing therapies. The development of ImmTAV for infectious diseases (HIV, HBV) and ImmTAAI for autoimmune diseases (Type 1 Diabetes, Atopic Dermatitis) positions Immunocore in other high-need therapeutic areas, aiming for functional cures or tissue-specific immune modulation, which could represent significant advancements over current treatments.

Comparison to Industry Standards

• KIMMTRAK's continued growth and status as standard of care in mUM in launched markets demonstrate strong market penetration and efficacy compared to previous limited options for this rare and aggressive form of melanoma.
• The Phase 3 TEBE-AM trial for 2L+ advanced cutaneous melanoma aims to address an unmet need where "no therapy having shown, to date, an OS improvement post checkpoint inhibitors in a randomized clinical trial," indicating a potential breakthrough if successful against current treatment paradigms.
• Brenetafusp's Phase 3 PRISM-MEL-301 trial in first-line advanced cutaneous melanoma targets an estimated 10,000 HLA-A*02:01 positive patients in the US and Europe, where "despite approved therapies, there remains a need for improved progression-free survival and OS." This suggests Immunocore is targeting areas where current standards (e.g., nivolumab or nivolumab + relatlimab) still leave room for improvement.
• The ImmTAV and ImmTAAI platforms aim for "functional cure" in infectious diseases and "tissue-specific down modulation" in autoimmune diseases, representing potentially transformative approaches beyond symptomatic management or broad immunosuppression, which could set new benchmarks in these therapeutic areas.

Stakeholder Impact

• Shareholders: Potential for sustained value through pipeline advancement and commercial growth, but short-term profitability decline may impact sentiment.
• Patients: Continued access to KIMMTRAK for uveal melanoma, and potential for new transformative therapies for advanced cutaneous melanoma, HIV, HBV, type 1 diabetes, and atopic dermatitis.
• Employees: Growth in pipeline and global commercial expansion suggests continued investment in business support functions.
• Customers (Healthcare Providers): Continued availability and expansion of KIMMTRAK, with new treatment options potentially emerging from the pipeline.

Next Steps

• Complete enrollment in the Phase 3 TEBE-AM trial in 1H 2026.
• Continue 1:1 randomization of HLA-A*02:01 positive patients in the PRISM-MEL-301 trial with brenetafusp 160 mcg + nivolumab or control arm.
• Continue evaluating brenetafusp in Phase 1/2 trial across multiple solid tumors (ovarian cancer, NSCLC).
• Continue enrolling patients in Phase 1 dose escalation trial for IMC-P115C (PRAME-A02 Half-Life Extended).
• Continue enrolling patients in Phase 1/2 dose escalation trial for IMC-R117C (PIWIL1) for colorectal and other GI cancers.
• Continue patient enrollment at higher doses in the multiple ascending dose part of the Phase 1/2 clinical trial for IMC-M113V (Gag-A02) for HIV.
• Present poster for IMC-I109V (Envelope-A02) for HBV at the 2025 American Association for the Study of Liver Diseases Meeting on November 7, 2025.
• File a CTA or IND for IMC-S118AI (PPI-A02) for type 1 diabetes in H2 2025.
• Plan to file a CTA/IND for IMC-U120AI (CD1a) for atopic dermatitis in 2026.
• Pay approximately $65 million in sales-related rebate accruals in Q4 2025.

Key Dates

Recommendation

While Immunocore demonstrates strong commercial growth for KIMMTRAK and significant progress in its clinical pipeline, the shift from a net profit to a net loss in Q3 2025, driven by increased R&D and SG&A expenses, introduces a degree of financial uncertainty. The robust cash position provides a buffer for continued investment, but investors should monitor the path to profitability and the success of late-stage clinical trials. The IDMC's dose selection for brenetafusp is a positive step, but the long-term value hinges on successful trial outcomes and market penetration of new indications and candidates. Therefore, a "hold" recommendation is appropriate, advising investors to maintain their current position while awaiting further clarity on financial performance and clinical milestones.

Keywords

Immunocore, IMCR, KIMMTRAK, tebentafusp, uveal melanoma, cutaneous melanoma, PRAME, brenetafusp, ImmTAC, ImmTAV, ImmTAAI, biotechnology, oncology, infectious diseases, autoimmune diseases, clinical trials, financial results, Q3 2025, biopharmaceutical, drug development, cancer therapy, HIV, hepatitis B, type 1 diabetes, atopic dermatitis